Create a Free Account
or
Create a Free Account
or
| # | Filing Date | Period End Date | Type | Report Link |
|---|---|---|---|---|
| No Data found | ||||
| # | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
|---|
Stifel analyst Rick Wise maintains Medtronic (NYSE:MDT) with a Hold and raises the price target from $90 to $105.
Medtronic announces U.S. clinical study for Hugo robotic-assisted surgery system in gynecological procedures.
Medtronic plc (NYSE:MDT) today announced the start of the Embrace Gynecology investigational device exemption (IDE) U.S. clinic...
Citigroup analyst Joanne Wuensch maintains Medtronic (NYSE:MDT) with a Buy and raises the price target from $101 to $112.
The U.S. Commerce Department, under the Trump administration, has launched a national security review of medical imports—includ...
Medtronic's Altaviva wins FDA approval as a minimally invasive implant for urge urinary incontinence, offering long-lasting...
